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scores were found between patients with and without 
COPD. Neither did the small group of pSS patients with 
ILD significantly differ in SGRQ scores in comparison to 
patients without ILD. Respiratory symptoms were com-
mon in pSS, but were not more common in patients with 
concomitant COPD. Since pulmonary involvement in pSS 
is associated with an increased mortality and respiratory 
symptoms is a poor marker for pulmonary involvement, we 
suggest that pulmonary function tests should be performed 
liberally in all pSS patients regardless of symptoms.
Keywords Sjögren’s syndrome · Pulmonary disease · 
Co-morbidities · Imaging
Introduction
Primary Sjögren’s syndrome (pSS) is a chronic autoim-
mune disease predominantly affecting exocrine glands 
resulting in diminished secretion and subsequent sicca 
symptoms [1, 2]. Extraglandular manifestations affecting 
various organs including the lungs are common amongst 
pSS patients [3–9] and approximately 50% of pSS patients 
report dry cough [3]. However, involvement of the respira-
tory system in pSS entails not only dry airways, but also 
obstructive airway disease [8], including chronic obstruc-
tive pulmonary disease (COPD) [5, 6], as well as intersti-
tial lung disease (ILD) [3, 4, 10], all of which can co-exist 
in the same patient. Furthermore, all types of respiratory 
involvement can result in respiratory symptoms. Although 
pulmonary involvement seems to be subclinical in a sub-
stantial fraction of pSS patients [4], concomitant pulmo-
nary involvement in pSS has been shown to be associated 
with a fourfold increased risk of mortality after 10  years 
of disease [7]. It has previously been shown that COPD 
Abstract Involvement of the respiratory system, in par-
ticular dry airways and chronic obstructive pulmonary 
disease (COPD), is common in patients with primary 
Sjögren’s syndrome (pSS). As respiratory symptoms are 
also common in pSS patients and may have different etiolo-
gies, we wanted to evaluate the amount and impact of res-
piratory symptoms in out-patients with pSS and to assess 
if such symptoms are related to concomitant COPD. The 
St George’s Respiratory Questionnaire (SGRQ) was used to 
assess respiratory symptoms. SGRQ scores were compared 
between 51 consecutive pSS patients, in an out-patient set-
ting, and 80 population-based controls. The patients were 
also studied by pulmonary function tests and CT scans 
of the lungs to assess signs of obstructive airway disease, 
including COPD, as well as to assess signs of interstitial 
lung disease (ILD). 41 and 18% of pSS patients were found 
to have COPD and radiographic signs of ILD, respectively. 
pSS patients had significantly higher SGRQ scores com-
pared to controls, but no significant differences in SGRQ 
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is a common finding in pSS patients, even among never-
smoking patients [5, 6]. To the best of our knowledge, no 
previous study has investigated to what degree COPD con-
tributes to the respiratory symptoms in pSS patients. Since 
concomitant lung disease is associated with a poorer sur-
vival in pSS patients, it is important to determine if evalua-
tion of pulmonary involvement, as evaluated by pulmonary 
function tests (PFTs) and radiographic evaluations of the 
lungs, to diagnose concomitant COPD and ILD, should 
be performed mainly in pSS patients with symptoms or if 
these should be performed regardless of symptoms. There-
fore, the aims of this study were (1) to compare respiratory 
symptoms in pSS patients with population-based controls 
and (2) to study whether such symptoms are associated 
with concomitant COPD, as this is a common finding in 
pSS patients in general.
Materials and methods
At the Department of Rheumatology, Skåne University 
Hospital Malmö, Sweden, consecutive pSS patients have 
been registered and clinically followed-up since 1984. 
Since our department is the only unit in this area fol-
lowing pSS patients, they represent a rather unselected 
spectrum of pSS patients. Fifty-one consecutive outpa-
tients diagnosed with pSS, according to the American-
European Consensus Group (AECG) criteria [11], seen 
from May to December in 2012, at our department were 
included in the study. These patients were in a previous 
study investigated for concomitant pulmonary involve-
ment by PFTs, CT scans of the lungs and the St George’s 
Respiratory Questionnaire (SGRQ) on respiratory symp-
toms [12, 13]. Briefly, PFT included static and dynamic 
spirometry, from which the vital capacity (VC), total lung 
capacity, residual volume, forced expiratory volume in 
1 s  (FEV1), and  FEV1/VC ratio, could be calculated. Dif-
fusion capacity for carbon monoxide (DL CO) was meas-
ured by the single-breath technique.  FEV1 and VC were 
measured before and after 1.0 mg of inhaled terbutaline 
and VC after reversibility test and  FEV1 reversibility was 
calculated. Radiographic features of the lungs were eval-
uated by conventional CT of the chest. Because signs of 
ILD as opposed to signs of obstructive pulmonary disease 
are less commonly detected in the general pSS popula-
tion, we mainly wanted to evaluate the latter in this study. 
Also due to radiation hygienic reasons, conventional CT 
was chosen instead of HRCT. The presence of a reticu-
lar pattern, ground glass attenuation, honeycombing, 
central as well as traction bronchiectasis, emphysema, 
pulmonary cysts, and air trapping was noted. COPD was 
defined according to the Global Initiative for Chronic 
Obstructive Lung disease (GOLD) criteria [14] and ILD, 
according to the presence of ground glass opacities, hon-
eycombing or peripheral traction bronchiectasis in CT 
scans of the lungs. Further characteristics of the patients 
are shown in Table  1. 80 population based controls 
(median age 61, range 31–80 years, 43 females), living in 
the county of Skåne, and denying having been diagnosed 
with a rheumatologic disease, asthma or COPD as well as 
using bronchodilators and/or inhalation steroids the last 6 
months, were randomly selected from the Swedish popu-
lation registry and included in the study. 49, 44 and 8% 
of the controls were never-smokers, prior smokers, and 
current smokers, respectively. A brief questionnaire on 
smoking habits and information on age, gender, height 
and weight as well as the SGRQ were mailed by post to 
the controls.
All subjects had to fill out a structured questionnaire 
on smoking habits with queries on current and past smok-
ing habits with mean cigarette smoking per day. Tobacco 
Table 1  Demographic and clinical characteristics of the patients 
with primary Sjögren’s syndrome included in the study
Results are presented as mean ± SD or as absolute numbers (% with 
abnormal findings)
GOLD Global Initiative for Chronic Obstructive Lung Disease, 
COPD chronic obstructive pulmonary disease, VC vital capacity, 
FEV1 forced expiratory volume in 1  s, DL CO diffusion capacity for 
carbon monoxide
Patients (n = 51)
Age (years) 60 ± 12
Female patients N (%) 49 (96)
Disease duration (years) 17 ± 12
Current/prior/never smokers N (%) 4/20/27 (8/39/53)
Anti-SS-A antibody seropositives N (%) 40 (78)
Anti-SS-B antibody seropositives N (%) 24 (47)
ANA seropositives N (%) 40 (78)
RF seropositives N (%) 26 (51)
IgG (g/L) 13.8 ± 5.1
C3 (g/L) 1.03 ± 0.25
C4 (g/L) 0.18 ± 0.07
Focus score ≥1 (positive/negative/not assessed) 
N (%)
37/3/11 (73/6/22)
ESSDAI total score 7 ± 6
ESSPRI total score 6 ± 2
Fulfilling GOLD criteria for COPD N (%) 21 (41)
VC (L) 3.3 ± 0.8
FEV1 (L) 2.3 ± 0.6
FEV1/VC ratio 0.69 ± 0.08
DL CO (mmol/min kPa) 6.5 ± 1.9
Radiographic signs of ILD of the below N (%) 9 (18)
 Peripheral traction bronchiectasias N (%) 4 (8)
 Ground glass opacities N (%) 6 (12)
 Honey combing N (%) 0 (0)
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consumption, expressed as pack-years, could thus be cal-
culated. Subjects were also asked to state their height and 
weight from which the body mass index (BMI) could be 
calculated. We used the Swedish version of the SGRQ 
to evaluate the respiratory symptoms and consequences 
of these [13]. The questionnaire generates four differ-
ent scores: symptoms, activity, impact and a total score 
based on the former three. Scores range from 0 to 100 
and the lower the score the better the health. The Swed-
ish version has been tested for reliability and validity and 
compares well with the original. The questionnaire has 
previously been described in more detail [12, 13]. After 
scoring the questionnaires, the controls were stratified 
into females and males and a linear regression analysis 
was performed in which age, BMI and pack-years were 
added as co-variates to calculate gender, age, BMI and 
pack-year standardised values for the SGRQ subscores 
and total score. From the equations of these analyses, 
expected values for the SGRQ subscores and total score 
in the pSS patients were calculated. The expected SGRQ-
scores, taking into account gender, age, tobacco con-
sumption and BMI, were then compared with the actual 
SGRQ-scores found in the pSS patients. To compare the 
SGRQ scores in pSS patients with COPD (pSS+COPD) 
vs. without COPD (pSS–COPD) we calculated the devia-
tion of SGRQ scores from expected values in each pSS 
patient and compared the groups. The same calculation 
was performed to compare pSS patients with (pSS+ILD) 
and without (pSS–ILD) radiographic signs of ILD.
Statistics
To calculate the expected SGRQ scores for the pSS-
patients a linear regression was performed. When com-
paring the expected SGRQ scores with the actual SGRQ 
scores in the pSS patients, a paired samples Student’s t 
test was used. When comparing the deviation in SGRQ-
results from expected values, between pSS+COPD with 
pSS–COPD and pSS+ILD with pSS–ILD, respectively, the 
Mann–Whitney U test was used. Results were presented if 
not stated otherwise as median (interquartile range) and p 
values < 0.05 were considered statistically significant.
Ethics
The study was approved by the local ethics board (Lund 
University 2015/310). All patients gave written informed 
consent and the study was performed according to the Dec-
laration of Helsinki.
Results
41% of pSS patients fulfilled GOLD criteria for COPD 
and 18% showed radiographic signs of ILD. pSS patients 
had significantly increased SGRQ symptoms (p < 0.001), 
SGRQ activity (p < 0.001), SGRQ impact (p < 0.001) 
as well as SGRQ total scores (p < 0.001) in comparison 
to expected scores based on the results of the population 
based controls (Fig. 1). However, there was no significant 
difference in the deviation of SGRQ symptoms, SGRQ 
activity, SGRQ impact or SGRQ total scores from expected 
values in pSS patients with and without COPD (Table 2). 
In addition, there was no significant difference in the devia-
tion of SGRQ symptoms, SGRQ activity, SGRQ impact or 
SGRQ total scores from expected values in pSS patients 
with and without radiographic signs of ILD (Table 2).
Discussion
In this study, we showed that respiratory symptoms were 
more common in pSS patients than in population-based 
controls, even after taking age, gender, tobacco consump-
tion and BMI into account. Furthermore, these symptoms 
lead to restrictions in daily physical activities and had psy-
chosocial consequences for the pSS patients. Although 
a large proportion of patients fulfilled GOLD criteria for 
COPD, concomitant COPD did not contribute significantly 
to the reported respiratory symptoms in these patients. 
Although the group of patients with concomitant ILD was 
too small to draw any firm conclusions, these patients did 
not significantly differ from patients without ILD with 
regard to respiratory symptoms either. Nevertheless, the 
results of the current study imply that airway sicca is the 
most likely cause of respiratory symptoms in unselected 
pSS patients. Another explanation could also be inflam-
matory processes in close proximity to the small airways 
resulting in bronchial hyperreactivity and respiratory symp-
toms [8, 15–17]. Since airway sicca, COPD and ILD may 
co-exist in the same patient, another explanation could also 
be that respiratory symptoms caused by COPD and ILD in 
pSS patients are obscured by concomitant superimposed 
symptoms due to airway sicca.
Early detection of pulmonary involvement seems 
important considering the increased mortality in pSS 
patients with pulmonary manifestations [7, 18, 19], par-
ticularly if improved disease-modifying treatments, in the 
future, gain a wider use in the treatment of pSS patients 
with systemic disease [4, 20]. Therefore, we suggest that 
patients with pSS should be evaluated by PFT, to screen 
for concomitant pulmonary involvement, both at base-
line and liberally at follow-up, regardless of respiratory 
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Fig. 1  Results of the St 
George’s Respiratory Question-
naire (SGRQ) in pSS patients 
and expected values based on 
the results from population 
based controls. The horizontal 
line in the middle of the box rep-
resents the median value and the 
height of the box the interquar-
tile range (IQR). The horizontal 
bars below and above the box 
define the range
Table 2  Deviation of SGRQ (ΔSGRQ) subscores from expected values in pSS patients with COPD (pSS+COPD) vs. pSS patients without 
COPD (pSS–COPD) as well as in pSS patients with ILD (pSS+ILD) vs. pSS patients without ILD (pSS–ILD)
Results are presented as deviation in points from expected values [median (IQR)]
pSS+COPD (n = 21) pSS–COPD (n = 30) p value
ΔSGRQ symptoms score 24.4 (6.5; 41.6) 21.3 (1.2; 36.7) 0.39
ΔSGRQ activity score 18.8 (6.3; 47.3) 21.8 (0.8; 35.6) 0.85
ΔSGRQ impact score 10.6 (0.1; 23.8) 6.6 (−0.7; 22.0) 0.42
ΔSGRQ total score 23.0 (2.5; 31.5) 18.5 (1.2; 27.4) 0.48
pSS+ILD (n = 9) pSS–ILD (n = 42) p value
ΔSGRQ symptoms score 33.6 (0.3; 49.1) 22.3 (3.1; 36.7) 0.54
ΔSGRQ activity score 34.7 (8.7; 50.3) 15.4 (−2.6; 38.7) 0.24
ΔSGRQ impact score 12.0 (1.2; 22.9) 7.9 (−0.6; 23.0) 0.60
ΔSGRQ total score 27.4 (5.3; 31.6) 14.4 (1.9; 27.6) 0.26
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symptoms, since respiratory symptoms seem to be a poor 
marker for concomitant COPD in pSS patients.
The strengths of our study were the use of consecutive 
patients, diagnosed with pSS in accordance with the gen-
erally acknowledged AECG criteria and the use of popu-
lation based controls. Limitations of the study include the 
limited size of the study with patients having relatively 
mild pulmonary involvement, considering the fact that 
none of the patients had radiographic signs of more severe 
ILD. Therefore, patients with more severe ILD may have 
more pronounced symptoms that the SGRQ would detect. 
Still, a substantial fraction of patients fulfilled GOLD cri-
teria for COPD, and the symptoms due to COPD could 
not be detected by the SGRQ in pSS patients although the 
SGRQ has previously been validated in ordinary COPD 
patients [13]. Secondly, the pSS patients in this study 
were, due to radiation hygienic purposes, only evalu-
ated by conventional and not high resolution CT (HRCT) 
scans, and therefore less likely to be diagnosed with con-
comitant ILD. However, according to a previous study, 
using HRCT in evaluation of pulmonary involvement in 
pSS patients, HRCT signs of ILD were quite rare in com-
parison with spirometric signs of COPD, in pSS patients 
in general [5]. Taken together, this implies that the asso-
ciation between respiratory symptoms and ILD has to be 
further studied in patients with more severe ILD. Thirdly, 
inclusion of a second positive control group consisting of 
COPD patients in general would have strengthened the 
findings of this study. Unfortunately, no second control 
group was studied. Finally, the presence of concomitant 
undiagnosed COPD, asthma and congestive heart disease, 
all possibly resulting in respiratory symptoms, was not 
ruled out amongst controls.
In conclusion, we showed that respiratory symptoms 
were more common amongst pSS patients than in the 
normal population. Concomitant COPD did not seem to 
significantly contribute to these, suggesting that other 
factors are more important in eliciting such symptoms in 
pSS patients, of which airway sicca is probably the most 
important. Since pulmonary involvement in pSS is asso-
ciated with an increased mortality and respiratory symp-
toms is a poor marker for pulmonary involvement, we 
suggest that PFT should be performed liberally in all pSS 
patients regardless of symptoms to enable early detection 
of pulmonary involvement in these patients.
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